ImmixBio Approves 4 Additional Clinical Trial Sites for IMX-110 Clinical Trials, Complementing Existing Soft Tissue Sarcoma Lead SiteGlobeNewsWire • 10/18/22
ImmixBio Completes GMP Manufacturing of Scaled-Up Batch of IMX-110 for Clinical TrialsGlobeNewsWire • 09/07/22
ImmixBio IMX-110 Demonstrated Improved Survival Over U.S. Food and Drug Administration Approved Drug Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company) in Connective Tissue Cancer Soft Tissue Sarcoma Mice StudyGlobeNewsWire • 05/20/22
ImmixBio Management Discusses Key Milestones, Drug Development Timelines and the IMMX Advantage at IMMX Milestone Day Event Held on April 5, 2022GlobeNewsWire • 04/05/22
Immix Biopharma, Inc. Announces IMMX Milestone Day to be Held on April 5, 2022GlobeNewsWire • 03/07/22
ImmixBio Initiates GMP Manufacturing of IMX-120, a Biologic for Inflammatory Bowel DiseaseGlobeNewsWire • 02/22/22
ImmixBio Management Answers Top-Voted Investor Questions at IMMX Investors Day February 1, 2022GlobeNewsWire • 02/01/22
ImmixBio Initiates IMX-110 GMP Manufacturing Scale-Up, Potentially Accelerating Clinical Trial DataGlobeNewsWire • 01/31/22
Immix Biopharma's IMX-110 / Anti-PD-1 Combo Therapy Shows Extended Median Survival In Animal StudiesBenzinga • 01/25/22
IMX-110 + anti-PD-1 Combination Produced Extended Median Survival in Genetic Pancreatic Cancer Mouse Model, Bolstering Planned 2022 IMX-110 Combination Clinical Trial RationaleGlobeNewsWire • 01/25/22
ImmixBio Announces Positive IMX-110 Phase 1b/2a Interim Clinical Trial Safety Data Demonstrating 100% Completion of Planned Treatment CyclesGlobeNewsWire • 01/19/22
ImmixBio IMX-110 Produced 50% Positive Response Rate in First-Line-Therapy-Resistant Cancer, Surpassing the Standard of Care in Mice StudyGlobeNewsWire • 01/12/22
Immix Biopharma Announces IMMX Investors Day to be Held on February 1, 2022 + Q&A Platform for All ShareholdersGlobeNewsWire • 01/06/22
IMMX Stock Alert: The Massive FDA Win That Has Immix Biopharma Blasting Higher TodayInvestorPlace • 01/03/22
Immix Shares Rally On FDA Rare Pediatric Disease Tag For Cancer Program In ChildrenBenzinga • 01/03/22